Reviewed Mar 2026 | PubMed sources
Active Market
United Kingdom is selected. The evidence comparison is still valid, but provider availability, legal positioning, and cost assumptions may still be staged for later rollout.

Retatrutide vs Survodutide: Head-to-Head Comparison

Both are investigational next-generation peptides for obesity. Retatrutide is a triple agonist (GIP/GLP-1/glucagon) with up to 24.2% weight loss — the highest ever reported. Survodutide is a dual agonist (GLP-1/glucagon) with up to 19% weight loss and strong MASH data. Neither is FDA-approved yet.

Side-by-Side Comparison

DimensionRetatrutideSurvodutide
Evidence LevelLevel B — Phase 2 RCT; Phase 3 ongoing (TRIUMPH)Level B — Phase 2 data; Phase 3 ongoing (SYNCHRONIZE)
FDA StatusNot approved; Eli Lilly Phase 3Not approved; Boehringer Ingelheim Phase 3
Weight Loss EfficacyUp to 24.2% (Phase 2 at 48 weeks)Up to 19% (Phase 2 at 46 weeks)
MechanismTriple agonist: GIP + GLP-1 + glucagonDual agonist: GLP-1 + glucagon
Liver Fat / MASH BenefitSignificant liver fat reduction observedSignificant liver fat reduction; dedicated MASH trials
Diabetes EfficacyHbA1c reduction up to 2.16% in Phase 2Glycemic improvements observed; less diabetes-specific data
Evidence Level
Retatrutide
Level B — Phase 2 RCT; Phase 3 ongoing (TRIUMPH)
Survodutide
Level B — Phase 2 data; Phase 3 ongoing (SYNCHRONIZE)
FDA Status
Retatrutide
Not approved; Eli Lilly Phase 3
Survodutide
Not approved; Boehringer Ingelheim Phase 3
Weight Loss Efficacy
Retatrutide
Up to 24.2% (Phase 2 at 48 weeks)
Survodutide
Up to 19% (Phase 2 at 46 weeks)
Mechanism
Retatrutide
Triple agonist: GIP + GLP-1 + glucagon
Survodutide
Dual agonist: GLP-1 + glucagon
Liver Fat / MASH Benefit
Retatrutide
Significant liver fat reduction observed
Survodutide
Significant liver fat reduction; dedicated MASH trials
Diabetes Efficacy
Retatrutide
HbA1c reduction up to 2.16% in Phase 2
Survodutide
Glycemic improvements observed; less diabetes-specific data

Peptide Overviews

Retatrutide

BHuman Studies

Retatrutide is an investigational triple-hormone receptor agonist developed by Eli Lilly. It simultaneously targets GIP, GLP-1, and glucagon receptors, achieving the highest weight loss ever reported in an obesity clinical trial — up to 24.2% at 48 weeks.

Weight LossNot Approved
View full Retatrutide profile →

Survodutide

BHuman Studies

Survodutide is a dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim. In Phase 3 trials, it demonstrates significant weight loss and is also being investigated for metabolic dysfunction-associated steatohepatitis (MASH/NAFLD).

Weight LossNot Approved
View full Survodutide profile →

Supplies for Both

Common research handling and preparation supplies for injectable peptide workflows.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Recommended Reading

Books covering peptide science, longevity research, and biohacking frameworks.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Retatrutide vs Survodutide: FAQ